Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature

por How, Joan, Hobbs, Gabriela
Publicado 2020

Biology and therapeutic targeting of molecular mechanisms in MPNs

por How, Joan, Garcia, Jacqueline S., Mullally, Ann
Publicado 2023

P1029: JAK2-CHIP IS ASSOCIATED WITH SIMILAR RISK OF CARDIOVASCULAR DISEASE AS JAK2-MPN

por Grevet, Jeremy, Leiva, Orly, Hobbs, Gabriela, How, Joan
Publicado 2023

Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients

por How, Joan, Story, Charlotte, Ren, Siyang, Neuberg, Donna, Rosovsky, Rachel P., Hobbs, Gabriela S., Connors, Jean M.
Publicado 2021

Immunologic Responses to Sars-Cov-2 Vaccination in Myeloproliferative Neoplasm Patients: Durability, Booster Responses, and Associations with Infections

por How, Joan, Gallagher, Kathleen M.E., Liu, Yiwen, Katsis, Katelin, Elder, Eva, Neuberg, Donna S., Reeves, Patrick M., Maus, Marcela V., Hobbs, Gabriela S.
Publicado 2022

Antibody and T-Cell Responses to COVID-19 Vaccination in Myeloproliferative Neoplasm Patients

por How, Joan, Gallagher, Kathleen M.E., Liu, Yiwen, DeMato, Ashley, Katsis, Katelin, Larson, Rebecca, Leick, Mark B., Neuberg, Donna S., Maus, Marcela V., Hobbs, Gabriela
Publicado 2021

Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients

por How, Joan, Gallagher, Kathleen M. E., Liu, Yiwen, Katsis, Katelin, Elder, Eva L., Larson, Rebecca C., Leick, Mark B., Neuberg, Donna, Maus, Marcela V., Hobbs, Gabriela S.
Publicado 2022

A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies

por How, Joan, Ren, Siyang, Lombardi‐Story, Jennifer, Bergeron, Meghan, Foster, Julia, Amrein, Phillip C., Brunner, Andrew M., Fathi, Amir T., Hock, Hanno, Khachatryan, Anna, Kikuchi, Hiroto, Ng, Mei Rosa, Moran, Jenna, Narayan, Rupa, Neuberg, Donna, Ramos, Aura, Som, Tina, Vartanian, Meghan, Chen, Yi‐Bin, Duda, Dan G., Hobbs, Gabriela S.
Publicado 2022

Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study

por Naranbhai, Vivek, Pernat, Claire A., Gavralidis, Alexander, St Denis, Kerri J., Lam, Evan C., Spring, Laura M., Isakoff, Steven J., Farmer, Jocelyn R., Zubiri, Leyre, Hobbs, Gabriela S., How, Joan, Brunner, Andrew M., Fathi, Amir T., Peterson, Jennifer L., Sakhi, Mustafa, Hambelton, Grace, Denault, Elyssa N., Mortensen, Lindsey J., Perriello, Lailoo A., Bruno, Marissa N., Bertaux, Brittany Y., Lawless, Aleigha R., Jackson, Monica A., Niehoff, Elizabeth, Barabell, Caroline, Nambu, Christian N., Nakajima, Erika, Reinicke, Trenton, Bowes, Cynthia, Berrios-Mairena, Cristhian J., Ofoman, Onosereme, Kirkpatrick, Grace E., Thierauf, Julia C., Reynolds, Kerry, Willers, Henning, Beltran, Wilfredo-Garcia, Dighe, Anand S., Saff, Rebecca, Blumenthal, Kimberly, Sullivan, Ryan J., Chen, Yi-Bin, Kim, Arthur, Bardia, Aditya, Balazs, Alejandro B., Iafrate, A. John, Gainor, Justin F.
Publicado 2022